Spyre Therapeutics (SYRE) Enterprise Value (2015 - 2026)
Spyre Therapeutics posted quarterly Enterprise Value of -$741.5 million for Q1 2026, down 31.67% year-on-year from -$1.1 billion in Q1 2025, and up 1.99% on a QoQ basis from -$756.5 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Enterprise Value data on file, last reported at -$741.5 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 31.67% year-over-year to -$741.5 million; the trailing twelve-month figure through Mar 2026 stood at -$741.5 million (down 31.67% YoY), and the FY2025 full-year result was -$756.5 million, down 25.8% from the prior year.
- Enterprise Value for Q1 2026 stood at -$741.5 million, up from -$756.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$38.5 million in Q1 2023 and bottomed at -$756.5 million in Q4 2025.
- The 5-year median for Enterprise Value is -$412.5 million (2024), against an average of -$358.8 million.
- The widest annual swing landed in 2022, when Enterprise Value soared 47.32%; it then slumped 1159.53% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$55.7 million in 2022, then sank by 508.99% to -$339.3 million in 2023, then plunged by 77.26% to -$601.4 million in 2024, then decreased by 25.8% to -$756.5 million in 2025, then increased by 1.99% to -$741.5 million in 2026.
- The last three Enterprise Value figures came in at -$741.5 million (Q1 2026), -$756.5 million (Q4 2025), and -$486.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -741.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -741.47 Mn |
| Dec 31, 2025 | -756.53 Mn |
| Sep 30, 2025 | -486.20 Mn |
| Jun 30, 2025 | -526.58 Mn |
| Mar 31, 2025 | -563.13 Mn |
| Dec 31, 2024 | -601.40 Mn |
| Sep 30, 2024 | -412.55 Mn |
| Jun 30, 2024 | -426.00 Mn |
| Mar 31, 2024 | -484.64 Mn |
| Dec 31, 2023 | -339.28 Mn |
| Sep 30, 2023 | -203.60 Mn |
| Jun 30, 2023 | -235.36 Mn |
| Mar 31, 2023 | -38.48 Mn |
| Dec 31, 2022 | -55.71 Mn |
| Sep 30, 2022 | -73.68 Mn |
| Jun 30, 2022 | -88.55 Mn |
| Mar 31, 2022 | -66.73 Mn |
| Dec 31, 2021 | -93.13 Mn |
| Sep 30, 2021 | -112.43 Mn |
| Jun 30, 2021 | -128.58 Mn |
| Mar 31, 2021 | -126.66 Mn |
| Dec 31, 2020 | -146.27 Mn |
| Sep 30, 2020 | -139.98 Mn |
| Jun 30, 2020 | -157.73 Mn |
| Mar 31, 2020 | -48.99 Mn |
| Dec 31, 2019 | -71.95 Mn |
| Sep 30, 2019 | -88.70 Mn |
| Jun 30, 2019 | -105.54 Mn |
| Mar 31, 2019 | -64.91 Mn |
| Dec 31, 2018 | -74.51 Mn |
| Sep 30, 2018 | -63.00 Mn |
| Jun 30, 2018 | -72.19 Mn |
| Mar 31, 2018 | -40.34 Mn |
| Dec 31, 2017 | -50.30 Mn |
| Sep 30, 2017 | -53.80 Mn |
| Jun 30, 2017 | -63.39 Mn |
| Mar 31, 2017 | -57.87 Mn |
| Dec 31, 2016 | -63.50 Mn |
| Sep 30, 2016 | -68.04 Mn |
| Jun 30, 2016 | -73.58 Mn |
| Mar 31, 2016 | -28.99 Mn |
| Dec 31, 2015 | -33.06 Mn |
| Sep 30, 2015 | -30.84 Mn |
| Jun 30, 2015 | -39.08 Mn |
| Mar 31, 2015 | -43.79 Mn |